Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has issued an update.
NetraMark Holdings Inc. announced the presentation of new data at the ISCTM Annual Meeting, showcasing their innovative AI-based tools for clinical trials in psychiatric disorders. These tools, leveraging advanced machine learning techniques, aim to improve the accuracy of predictive models and the identification of effective treatments by deconstructing patient populations into actionable subgroups. The company demonstrated significant improvements in model accuracy and specificity for major depressive disorder and schizophrenia trials, highlighting the potential for these tools to transform CNS clinical trials and benefit stakeholders by offering more precise treatment insights.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software, specializing in clinical trial analytics. The company focuses on enhancing predictive modeling and patient stratification in psychiatric clinical trials through its machine learning tools, primarily targeting disorders such as major depressive disorder and schizophrenia.
YTD Price Performance: 7.43%
Average Trading Volume: 8,232
Technical Sentiment Consensus Rating: Sell
Learn more about AIAI stock on TipRanks’ Stock Analysis page.